Prescription Drugs: Global Outlook to 2008

Published: October 2004

123 pages, Can be printed; fully searchable PDF format; TOC hyperlinks and Internet hyperlinks


SKU: TPR3153



$1,695.00 (US Dollars) PDF Single User License

$1,995.00 (US Dollars) PDF Single Office License (2 to 5 users)

$2,295.00 (US Dollars) PDF Corporate Site License





This report is about the global market for prescription drugs and estimates the market outlook to 2008.  Readers receive detailed data and analysis about important global pharmaceutical industry developments.  The research report discusses key industry activities including alliances, disease demographics to target major diseases, distribution channels and market trends.


The research study shows that companies are facing challenging times ahead as drug patent expirations approach and lists patent expirations to 2008. The development of new drug pipelines and how companies can get their drugs approved around the globe are also key challenges that the pharmas must face.  The report discusses what pharma companies must do to market and distribute their approved products to patients around the world.


While the global economy has had its ups and downs, this report projected that the market will grow to about $655.8 billion in 2008 and will grow at a rate of about 7.3% (CAGR).


The pharmaceutical industry faces numerous challenges that could be helped with newer business approaches.  This report looks at the industry from the viewpoint of leading disease categories and reveals what the key health issues are through disease demographic data from around the globe.  This report analyzes the disease categories of the top 276 drug products and ranks the best selling areas and products. This interesting data is projected to 2008.


Pharma and biotech industry executives, product managers, marketers, planners, entrepreneurs, VCs, investors, academic researchers and consultants would find this report a useful information source. The report discusses the numerous pharma industry topics with interesting and useful findings.  Thirty-two tables and seventeen figures illustrate the findings.  Detailed information about the business and R&D activities of the top pharma companies is listed in many areas of this report.  



Table Of Contents


1.Disease Demographics and the Rx Drug Market

   Pharmaceutical Planning and Disease Statistics

   The Scale of Major Disease Populations

  Health Risks and Death Linked to `Modern' Lifestyle

2.Leading Rx Drugs, Revenues and Drug Companies

   The Leading Twenty Prescription Drugs

     Leading Twenty Rx Drugs by Disease Categories

     Leading Twenty Rx Drugs by Top Pharma Companies

   The Best Selling 276 Prescription Drugs

     The Best Selling Drugs by Disease Categories

3.Drug Market Distribution, Price and Cost Arrangement

   Approaches to Regional Price Setting

   A Case Study of a Drug Distribution Channel

     Distribution Supply Chain and Distributors

     Example of How Rx Drugs Reach Patients (HMO)

4.Pharma Partnering and M&A Trends

   Review of Pharmaceutical Partnerships

   Comparing Alliances and M&As

   Key Findings About Alliances and M&As

   Background to the Following Data Tables

5.Patent Expiries and New Drug Pipelines

   The Impact of Nearing Patent Expirations

   Late Stage Drug Pipeline in 2003

6.Navigating World Drug Regulatory Organizations Drug

   R&D and Regulatory Approval Processes

     Drug Approvals in the USA (North America)

     Overview of the Drug Approval Process in the

     USA (FDA)

   Drug Approvals in the European Union (EU)

     Overview of the Drug Approval Process in the

     European Union

     `Mutual Recognition' Principle

     The Centralized Approval Procedure

     Decentralized Approval Procedure

   Drug Approvals in Japan

     Overview of the Drug Approval Process in Japan

     Applications for Approval of Drugs Manufactured

     Outside of Japan

     Japan's Priority Review System

     The Orphan Drug Designation

  Regional Drug Regulatory Issues to Consider

     USA (North America)

     The European Union

     In Japan

7.The Global Rx Drug Market Size and Outlook to 2008

   Rx Drug Market Size of the Developed World

   Selected Top 276) Global Rx Drug Market Size by

   Disease and Revenues

   Top Six Market Segments and Subsegments

8.Conclusions and Issues to Consider

   Drug Companies Use Disease Demographics

     Epidemiology Based Pharmaceutical Planning Large

     Disease Populations Point to Potential Marketing


     Health Risk Factors Lead to Sickness & Death

   Key Points about Global Regulators and Issues

     Need for Government Drug Regulatory Approval

     International Drug R&D and Approval Processes

     Regulatory Trends

   Drug Patent Expiration Dates and New Drug

     Pipeline Patent Expirations Looming to

     Cause Big Losses Current Drug R&D

     Pipeline is Weak

   Drug Pricing & Distribution Arrangements

     Pricing Arrangements

     Drug Distribution Supply Chain

   Pharma Alliances and M&As

     Alliance Trends

   Rx Drug Market Size

   Best Selling Rx Drugs

   Issues to Consider


   Pharmaceutical Business Glossary

   Contacts to the Top 55 Pharma Companies

   Links to Worldwide Drug Regulatory Organizations


List of Tables


Table 1. Major Disease Populations by Annual New Patients

Table 2. Major Disease Populations by Total Existing


Table 3. Disease Populations in the Developed World

Table 4. Major Health Risk Factors Leading to Death

Table 5. Leading 20 Rx Drugs Global Sales ($M)

Table 6. Leading 15 Disease Categories by Global Sales

Table 7. Disease Category Definitions Used in this Section

Table 8. Rx Drugs by Disease Indication and Global Sales

Table 9. Rx Drug Pricing Tiers and Channels by Region

Table 9. Rx Drug Pricing Tiers and Channels by Region

Table 10. Model of US Pricing for Brand Name Rx Drugs

Table 11. Top Level of US Wholesale Rx Drug Distribution


Table 12. Details of the US Retail Pharmacy Channel

Table 13. Key Rx Drug Distributors by International Region

Table 14. Map of Pharma Alliances and M&As

Table 15. Pharma Strategic Alliances and M&As by Major


Table 16. Alliances and M&As, 2003

Table 17. Alliances and M&As, 2002

Table 18. Alliances and M&As, 2001

Table 19. Alliances and M&As, 2000

Table 20. Summary of Drug Patent Expirations and Lost


Table 21. Drug Patent Expirations to 2008

Table 22. Drug Patent Expirations by Disease Category and


Table 23. Drug Pipeline by Clinical Phase in 2003

Table 24. Drug Pipeline Summary by Disease for 2003

Table 25. Late Stage Rx Drug Development Pipeline (2003)

Table 26. Relationship of Drug Regulation to Drug


Table 27. Total Audited World Rx Drug Sales by Regions,


Table 28. Estimated Global Rx Drug Sales by Regions, 2002-


Table 29. Top 10 Products in 2002 Global Rx Drug Sales

Table 30. Top 276 Human Rx Drug Global Market Size Sorted

          by 2003 Revenues ($M) and Disease Segments

          (Summary), 2002-2008E

Table 31. Top 276 Human Rx Drug Global Market Size Sorted

           by CAGR and Disease Segments (Summary), 2002-2008E

Table 32. Top 276 Human Rx Drug Global Market Size by

           Disease (Detail) ($M) 2002-2008E


List of Illustrations


Figure 1. An Rx Drug Distribution Arrangement

Figure 2. Map of Strategic Alliances and M&As

Figure 3. Selected M&As by Valuation ($M)

Figure 4. Pharma Strategic Alliances and M&As by Major


Figure 5. Navigating the Drug R&D and Approval Process

Figure 6. The US FDA New Drug Approval Process Flowchart

Figure 7. EU Centralized Drug Approval Procedure Flowchart

Figure 8. EU Decentralized New Drug Approval Procedure


Figure 9. Japan MHLW New Drug Approval Flowchart

Figure 10. Estimated Selected (Top 276) Human Rx Drug Global

           Market Size by Revenues ($M) and Disease Segments,


Figure 11. Comparison of Disease Segment Market Shares for

           the Selected (Top 276) Global Human Rx Drug Market,

           2002 and 2008

Figure 12. Market Size by the Estimated `Cardiovascular'

           Segment Revenues, 2002-2008

Figure 13. Market Size by Estimated `CNS' Subsegment

           Revenues, 2002-2008

Figure 14. Market Size by Estimated `Infections' Subsegment

           Revenues, 2002-2008

Figure 15. Market Size by Estimated `Respiratory & Allergy'

           Subsegment Revenues, 2002-2008

Figure 16. Market Size by the Estimated `Gastrointestinal'

           Subsegment Revenues, 2002-2008

Figure 17. Market Size by the Estimated `Cancer' Subsegment

           Revenues, 2002-2008


For more information or to order the above publications,
call 1-510-796-9129 or fax 1-510-796-9129.

 Copyright © 1996-2012 TAKEDA PACIFIC.  All Rights Reserved.